Literature DB >> 26286179

The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward.

Sjef van der Linden1, Nurullah Akkoc, Matthew A Brown, Philip C Robinson, Muhammad A Khan.   

Abstract

Classification criteria should facilitate selection of similar patients for clinical and epidemiologic studies, therapeutic trials, and research on etiopathogenesis to enable comparison of results across studies from different centers. We critically appraise the validity and performance of the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis (axSpA). It is still debatable whether all patients fulfilling these criteria should be considered as having true axSpA. Patients with radiographically evident disease by the ASAS criteria are not necessarily identical with ankylosing spondylitis (AS) as classified by the modified New York criteria. The complex multi-arm selection design of the ASAS criteria induces considerable heterogeneity among patients so classified, and applying them in settings with a low prevalence of axial spondyloarthritis (SpA) greatly increases the proportion of subjects falsely classified as suffering from axial SpA. One of the unmet needs in non-radiographic form of axial SpA is to have reliable markers that can identify individuals at risk for progression to AS and thereby facilitate early intervention trials designed to prevent such progression. We suggest needed improvements of the ASAS criteria for axSpA, as all criteria sets should be regarded as dynamic concepts open to modifications or updates as our knowledge advances.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26286179     DOI: 10.1007/s11926-015-0535-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  55 in total

Review 1.  The changing clinical picture and epidemiology of spondyloarthritis.

Authors:  Astrid van Tubergen
Journal:  Nat Rev Rheumatol       Date:  2014-11-11       Impact factor: 20.543

2.  Identifying axial spondyloarthritis in Dutch primary care patients, ages 20-45 years, with chronic low back pain.

Authors:  Lonneke van Hoeven; Jolanda Luime; Huub Han; Yvonne Vergouwe; Angelique Weel
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-03       Impact factor: 4.794

3.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

4.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Authors:  M Dougados; S van der Linden; R Juhlin; B Huitfeldt; B Amor; A Calin; A Cats; B Dijkmans; I Olivieri; G Pasero
Journal:  Arthritis Rheum       Date:  1991-10

5.  Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis.

Authors:  Heiner Appel; Gisela Ruiz-Heiland; Joachim Listing; Jochen Zwerina; Martin Herrmann; Ruediger Mueller; Hildrun Haibel; Xenofon Baraliakos; Axel Hempfing; Martin Rudwaleit; Joachim Sieper; Georg Schett
Journal:  Arthritis Rheum       Date:  2009-11

6.  Assessment of SpondyloArthritis International Society criteria for axial spondyloarthritis in chronic back pain patients with a high prevalence of HLA-B27.

Authors:  Gunnstein Bakland; Rikke Alsing; Kulbir Singh; Johannes C Nossent
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-03       Impact factor: 4.794

7.  Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Authors:  John C Davis; Désirée Van Der Heijde; Jurgen Braun; Maxime Dougados; John Cush; Daniel O Clegg; Alan Kivitz; Roy Fleischmann; Robert Inman; Wayne Tsuji
Journal:  Arthritis Rheum       Date:  2003-11

8.  Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis.

Authors:  Roman Fischer; David C Trudgian; Cynthia Wright; Gethin Thomas; Linda A Bradbury; Matthew A Brown; Paul Bowness; Benedikt M Kessler
Journal:  Mol Cell Proteomics       Date:  2011-10-13       Impact factor: 5.911

9.  Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?

Authors:  Carla G S Saad; Ana C M Ribeiro; Julio C B Moraes; Liliam Takayama; Celio R Goncalves; Marcelo B Rodrigues; Ricardo M de Oliveira; Clovis A Silva; Eloisa Bonfa; Rosa M R Pereira
Journal:  Arthritis Res Ther       Date:  2012-10-12       Impact factor: 5.156

10.  Ankylosing spondylitis is associated with the anthrax toxin receptor 2 gene (ANTXR2).

Authors:  T Karaderi; S M Keidel; J J Pointon; L H Appleton; M A Brown; D M Evans; B P Wordsworth
Journal:  Ann Rheum Dis       Date:  2014-08-28       Impact factor: 19.103

View more
  18 in total

Review 1.  Unmet Needs in Axial Spondyloarthritis.

Authors:  Ennio Lubrano; Antonia De Socio; Fabio Massimo Perrotta
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

Review 2.  Axial spondyloarthritis: concept, construct, classification and implications for therapy.

Authors:  Philip C Robinson; Sjef van der Linden; Muhammad A Khan; William J Taylor
Journal:  Nat Rev Rheumatol       Date:  2020-12-23       Impact factor: 20.543

Review 3.  Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria.

Authors:  Fabian Proft; Denis Poddubnyy
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-05-17       Impact factor: 5.346

Review 4.  [Classification criteria for rheumatic diseases].

Authors:  H Zeidler
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

5.  Validity and reliability of the Short Form 36 Health Surveys (SF-36) among patients with spondyloarthritis in Singapore.

Authors:  Yu Heng Kwan; Warren Weng Seng Fong; Nai Lee Lui; Si Ting Yong; Yin Bun Cheung; Rahul Malhotra; Truls Østbye; Julian Thumboo
Journal:  Rheumatol Int       Date:  2016-09-23       Impact factor: 2.631

Review 6.  Value-Based Healthcare in Rheumatology: Axial Spondyloarthritis and Beyond.

Authors:  David F L Liew; Jonathan Dau; Philip C Robinson
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

Review 7.  Therapeutic Potential of Triptolide in Treating Bone-Related Disorders.

Authors:  Wu Gang; Hu Hao; Huang Yong; Feng Ruibing; Li Chaowen; Huang Yizheng; Li Chao; Zhang Haitao
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

Review 8.  ASAS classification criteria for axial spondyloarthritis: time to modify.

Authors:  Nurullah Akkoc; Muhammad A Khan
Journal:  Clin Rheumatol       Date:  2016-04-19       Impact factor: 2.980

9.  Human brucellosis mimicking axial spondyloarthritis: a challenge for rheumatologists when applying the 2009 ASAS criteria.

Authors:  Cong Ye; Gui-Fen Shen; Shou-Xin Li; Ling-Li Dong; Yi-Kai Yu; Wei Tu; Ying-Zi Zhu; Shao-Xian Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-05

10.  Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population-Based Cohort Study.

Authors:  Runsheng Wang; Sherine E Gabriel; Michael M Ward
Journal:  Arthritis Rheumatol       Date:  2016-06       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.